Displaying 1 - 20 of 314
Download
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published
MHRA-102339-PIP01-26
  • Zelenectide pevedotin
  • Treatment of urothelial carcinoma.
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102320-PIP01-26
  • Zelenectide pevedotin
  • Treatment of breast cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101810-PIP01-25
  • Livmoniplimab
  • Treatment of all conditions included in the category of malignant neoplasms except melanoma, central nervous neoplasms, haematopoietic and lymphoid tissues neoplasms.
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102212-PIP01-25
  • sotatercept
  • Treatment of pulmonary hypertension due to left heart disease
  • Cardiovascular Diseases
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102192-PIP01-25
  • casdatifan
  • Treatment of renal cell carcinoma (RCC)
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102318-PIP01-26
  • Taletrectinib adipate
  • Treatment of non-small cell lung cancer
  • Not available at present
  • DOVBLERON
  • IBTROZI
  • IBTROZI
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102197-PIP01-25
  • DIFLUNISAL
  • Treatment of transthyretin amyloidosis
  • Attrogy
  • Attrogy
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102198-PIP01-25
  • Humanized IgG1 monoclonal antibody against thymic stromal lymphopoietin
  • Treatment of nasal polyposis
  • Oto-Rhino-Laryngology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102330-PIP01-26
  • Vimseltinib
  • Treatment of tenosynovial giant cell tumour
  • ROMVIMZA
  • ROMVIMZA
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102221-PIP01-25
  • Zanzalintinib
  • Treatment of colorectal cancer
  • Treatment of renal cell carcinoma
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102194-PIP01-25
  • Zanidatamab
  • Treatment of gastric, gastroesophageal junction and oesophageal adenocarcinoma.
  • Ziihera
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102196-PIP01-25
  • [4-(1-Methyl-1H-pyrazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1-yl-propoxy)- imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine
  • Treatment of gastrointestinal stromal tumours
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102287-PIP01-25
  • Clostridium botulinum, neurotoxin serotype A/B
  • Treatment of skin wrinkling
  • Neurology
  • Dermatology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102115-PIP01-25
  • Olomorasib
  • Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue neoplasms)
  • Treatment of malignant neoplasms of the central nervous system
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102216-PIP01-25
  • bimekizumab
  • Treatment of Palmoplantar Pustulosis
  • Bimzelx
  • Bimzelx
  • Bimzelx
  • Bimzelx
  • Dermatology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102188-PIP01-25
  • Tavapadon
  • Treatment of Parkinson’s disease
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102179-PIP01-25
  • aceclidine
  • Treatment of presbyopia
  • VIZZ VIZZ (aceclidine) 14.66 mg/mL eye drops solution
  • VIZZ (aceclidine ophthalmic solution) 1.44%, for topical ophthalmic use
  • Ophthamology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102273-PIP01-25
  • EZETIMIBE
  • ATORVASTATIN
  • Treatment of hypercholesterolaemia
  • Prevention of cardiovascular events
  • Ezetimibe/Atorvastatin 10mg/10mg Film-coated Tablets
  • Ezetimibe/Atorvastatin 10mg/20mg Film-coated Tablets
  • Ezetimibe/Atorvastatin 10mg/40mg Film-coated Tablets
  • Ezetimibe/Atorvastatin 10mg/80mg Film-coated Tablets
  • Cardiovascular Diseases
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102153-PIP01-25
  • Human IgG1 monoclonal antibody against folate receptor alfa conjugated to samrotecan
  • Treatment of ovarian cancer, fallopian tube cancer and peritoneal cancer.
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102137-PIP01-25
  • izalontamab brengitecan
  • Treatment of lung cancer
  • Treatment of breast cancer
  • Treatment of urothelial carcinoma
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
Download XLSX